BOT Announces Promotion and Focus on NDA Approval Readiness
Filed with ASX · · 3 pages · English
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings CallBotanix Pharmaceuticals Limited on 6ix
Earlier from Botanix Pharmaceuticals
- Positive BTX 1702 Phase 1b/2 Clinical Study for Rosacea
- BOT Submits FDA New Drug Application for Sofpironium Bromide
- Issue of First $7.0m Tranche of A$7.5m Placement Completed
- Botanix Completes Successful A$7.5m Placement
- Preliminary Final Report
Later from Botanix Pharmaceuticals
- Botanix receives A$3.7m R&D Tax Incentive Refund
- A$5 million Institutional Placement and Share Purchase Plan
- Share Purchase Plan Opens
- Placement Completion and Results of Share Purchase Plan
- Confirmation Sofpironium Bromide NDA Formally Under Review
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals